Matching articles for "CYP2C19"

Inhibitors and Inducers of CYP Enzymes, P-Glycoprotein, and Other Transporters (online only)

   
The Medical Letter on Drugs and Therapeutics • September 21, 2020;  (Issue 1607)
...
View the Inhibitors and Inducers of CYP Enzymes, P-Glycoprotein, and Other Transporters tables
Med Lett Drugs Ther. 2020 Sep 21;62(1607):e152-3 | Show Full IntroductionHide Full Introduction

Table: Inhibitors and Inducers of CYP Enzymes and P-Glycoprotein (online only)

   
The Medical Letter on Drugs and Therapeutics • March 27, 2017;  (Issue 1517)
...
View the Inhibitors and Inducers of CYP Enzymes and P-Glycoprotein table
Med Lett Drugs Ther. 2017 Mar 27;59(1517):e56-7 | Show Full IntroductionHide Full Introduction

Inhibitors and Inducers of CYP Enzymes and P-glycoprotein (online only)

   
The Medical Letter on Drugs and Therapeutics • May 27, 2013;  (Issue 1417)
...
The tables below list the drugs that induce or inhibit cytochrome P450 enzymes or P-glycoprotein.
Med Lett Drugs Ther. 2013 May 27;55(1417):e44 | Show Full IntroductionHide Full Introduction

In Brief: Poor Metabolizers of Clopidogrel (Plavix)

   
The Medical Letter on Drugs and Therapeutics • May 3, 2010;  (Issue 1337)
The FDA has required the manufacturer of Plavix, an antiplatelet drug used in addition to aspirin to prevent cardiovascular events in high-risk patients,1 to add a boxed warning to the package insert about the...
The FDA has required the manufacturer of Plavix, an antiplatelet drug used in addition to aspirin to prevent cardiovascular events in high-risk patients,1 to add a boxed warning to the package insert about the risk of a poor response to the drug in patients with genetic polymorphisms of the cytochrome P450 enzyme CYP2C19. Clopidogrel is a prodrug and CYP2C19 is mainly responsible for its bioactivation. The Medical Letter reported last year that several studies have found higher rates of cardiovascular events, including stent thrombosis, in patients with these polymorphisms taking clopidogrel.2

At least one genetic polymorphism leading to poor metabolism of clopidogrel has been reported to occur in 15% of Caucasians, 17% of African Americans and 30% of Asians.3 Since many patients take clopidogrel to protect against life-threatening events, and some continue to do so for extended periods of time, it might be worthwhile to test for these polymorphisms. Such tests, requiring small amounts of blood or saliva, are commercially available from clinical laboratories. More directly, patients who are taking clopidogrel could have platelet aggregation assays to determine whether the drug is being activated.

However, the best course of action for patients who prove to be poor metabolizers of clopidogrel is not clear. They could be treated with higher doses of clopidogrel, but the doses that would be safe and effective in such patients have not been established. Alternatively, they could be treated with prasugrel (Effient), a similar antiplatelet drug that does not require CYP2C19 for activation, instead of clopidogrel, but prasugrel has a greater effect on platelets and may cause more bleeding.4

1. Antiplatelet and anticoagulant drugs. Treat Guidel Med Lett 2008; 6:29.
2. PPI interactions with clopidogrel revisited. Med Lett Drugs Ther 2009; 51:13.
3. Z Desta et al. Clinical significance of the cytochrome P450 2C19 genetic polymorphism. Clin Pharmacokinet 2002; 41:913.
4. Prasugrel (Effient) vs. clopidogrel (Plavix). Med Lett Drugs Ther 2009; 51:69.

Download: U.S. English
Med Lett Drugs Ther. 2010 May 3;52(1337):33 | Show Full IntroductionHide Full Introduction

Drugs for Depression and Bipolar Disorder

   
The Medical Letter on Drugs and Therapeutics • May 1, 2010;  (Issue 93)
Drugs are not the only treatment for mood disorders. Psychotherapy remains an important component in the management of these disorders, and electroconvulsive therapy (ECT) has a long history of efficacy and...
Drugs are not the only treatment for mood disorders. Psychotherapy remains an important component in the management of these disorders, and electroconvulsive therapy (ECT) has a long history of efficacy and safety when drugs are ineffective, poorly tolerated or cannot be used. Some drugs are recommended here for indications that have not been approved by the FDA.
Treat Guidel Med Lett. 2010 May;8(93):35-42 | Show Full IntroductionHide Full Introduction

Antifungal Drugs

   
The Medical Letter on Drugs and Therapeutics • December 1, 2009;  (Issue 88)
The drugs of choice for treatment of some fungal infections are listed. Some of the indications and dosages recommended here have not been approved by the FDA. More detailed guidelines are available online from...
The drugs of choice for treatment of some fungal infections are listed. Some of the indications and dosages recommended here have not been approved by the FDA. More detailed guidelines are available online from the Infectious Diseases Society of America (www.idsociety.org).
Treat Guidel Med Lett. 2009 Dec;7(88):95-102 | Show Full IntroductionHide Full Introduction

Prasugrel (Effient) vs. Clopidogrel (Plavix)

   
The Medical Letter on Drugs and Therapeutics • September 7, 2009;  (Issue 1320)
The FDA has approved prasugrel (Effient - Lilly/Daiichi Sankyo), an oral antiplatelet drug, for use with aspirin to reduce the rate of thrombotic cardiovascular events in patients with acute coronary syndromes...
The FDA has approved prasugrel (Effient - Lilly/Daiichi Sankyo), an oral antiplatelet drug, for use with aspirin to reduce the rate of thrombotic cardiovascular events in patients with acute coronary syndromes (ACS) being managed with percutaneous coronary intervention (PCI). It will compete with clopidogrel (Plavix) for such use.
Med Lett Drugs Ther. 2009 Sep 7;51(1320):69-70 | Show Full IntroductionHide Full Introduction

Lacosamide for Epilepsy

   
The Medical Letter on Drugs and Therapeutics • June 29, 2009;  (Issue 1315)
The FDA has approved lacosamide (Vimpat - UCB Pharma) for oral or intravenous (IV) use as add-on therapy in adults with partial-onset...
The FDA has approved lacosamide (Vimpat - UCB Pharma) for oral or intravenous (IV) use as add-on therapy in adults with partial-onset seizures.
Med Lett Drugs Ther. 2009 Jun 29;51(1315):50-2 | Show Full IntroductionHide Full Introduction

Dexlansoprazole (Kapidex) for GERD and Erosive Esophagitis

   
The Medical Letter on Drugs and Therapeutics • March 23, 2009;  (Issue 1308)
The FDA has approved the proton-pump inhibitor (PPI) dexlansoprazole (Kapidex - Takeda), a delayed release formulation of the R-enantiomer of lansoprazole (Prevacid - Takeda), for treating and maintaining...
The FDA has approved the proton-pump inhibitor (PPI) dexlansoprazole (Kapidex - Takeda), a delayed release formulation of the R-enantiomer of lansoprazole (Prevacid - Takeda), for treating and maintaining healing of erosive esophagitis and for treatment of heartburn associated with non-erosive gastroesophageal reflux disease (GERD).
Med Lett Drugs Ther. 2009 Mar 23;51(1308):21-2 | Show Full IntroductionHide Full Introduction

PPI Interactions with Clopidogrel Revisted

   
The Medical Letter on Drugs and Therapeutics • February 23, 2009;  (Issue 1306)
Current guidelines recommend use of a proton pump inhibitor (PPI) to decrease the risk of gastrointestinal bleeding in patients taking clopidogrel (Plavix) with aspirin. A recent issue of The Medical Letter...
Current guidelines recommend use of a proton pump inhibitor (PPI) to decrease the risk of gastrointestinal bleeding in patients taking clopidogrel (Plavix) with aspirin. A recent issue of The Medical Letter considered whether omeprazole (Prilosec, and others) or other PPIs could interfere with the antiplatelet effect of clopidogrel. The conclusion was that patients taking both drugs should probably continue to do so until more data became available. Several new publications require reconsideration of that recommendation.
Med Lett Drugs Ther. 2009 Feb 23;51(1306):13-4 | Show Full IntroductionHide Full Introduction

PPI Interactions with Clopidogrel

   
The Medical Letter on Drugs and Therapeutics • January 12, 2009;  (Issue 1303)
Clopidogrel (Plavix), which prevents arterial thrombosis by inhibiting platelet activation, is commonly prescribed (usually with aspirin) for months after acute coronary syndromes and stent implantation. It may...
Clopidogrel (Plavix), which prevents arterial thrombosis by inhibiting platelet activation, is commonly prescribed (usually with aspirin) for months after acute coronary syndromes and stent implantation. It may also, however, increase the risk of bleeding. Therefore, a proton pump inhibitor (PPI) such as omeprazole (Prilosec, and others) is often given concurrently to decrease the risk of gastrointestinal (GI) bleeding. Some reports have suggested that omeprazole may interfere with the antiplatelet effect of clopidogrel.
Med Lett Drugs Ther. 2009 Jan 12;51(1303):2-3 | Show Full IntroductionHide Full Introduction

Extended-Release Fluvoxamine (Luvox CR)

   
The Medical Letter on Drugs and Therapeutics • June 30, 2008;  (Issue 1289)
Fluvoxamine maleate, a selective serotonin reuptake inhibitor (SSRI) that has been available for many years in an immediate-release formulation (Luvox, and others) for treatment of obsessive-compulsive disorder...
Fluvoxamine maleate, a selective serotonin reuptake inhibitor (SSRI) that has been available for many years in an immediate-release formulation (Luvox, and others) for treatment of obsessive-compulsive disorder (OCD) in children and adults, has now been approved by the FDA in an extended-release formulation (Luvox CR - Jazz Pharmaceuticals) for treatment of OCD and social anxiety disorder (SAD) in adults.
Med Lett Drugs Ther. 2008 Jun 30;50(1289):50-1 | Show Full IntroductionHide Full Introduction

Etravirine (Intelence) for HIV Infection

   
The Medical Letter on Drugs and Therapeutics • June 16, 2008;  (Issue 1288)
Etravirine (Intelence - Tibotec), a new non-nucleoside reverse transcriptase inhibitor (NNRTI), has received fast-track FDA approval for use in combination therapy in treatment-experienced adults who have HIV-1...
Etravirine (Intelence - Tibotec), a new non-nucleoside reverse transcriptase inhibitor (NNRTI), has received fast-track FDA approval for use in combination therapy in treatment-experienced adults who have HIV-1 infection resistant to an NNRTI and other antiretroviral agents.
Med Lett Drugs Ther. 2008 Jun 16;50(1288):47-8 | Show Full IntroductionHide Full Introduction

AmpliChip CYP450 Test

   
The Medical Letter on Drugs and Therapeutics • August 15, 2005;  (Issue 1215)
The FDA recently cleared the AmpliChip CYP450 Test (Roche), which analyzes blood-derived DNA to detect genetic variations in the activity of cytochrome P450 (CYP) enzymes CYP2D6 and CYP2C19 and determines the...
The FDA recently cleared the AmpliChip CYP450 Test (Roche), which analyzes blood-derived DNA to detect genetic variations in the activity of cytochrome P450 (CYP) enzymes CYP2D6 and CYP2C19 and determines the metabolizer status of the patient. The test is intended to help guide clinicians in prescribing individualized drug therapy. About 25% of all drugs, including many antidepressants and antipsychotics, are substrates of either CYP2D6 or CYP2C19. The test is being promoted initially to psychiatrists.
Med Lett Drugs Ther. 2005 Aug 15;47(1215):71-2 | Show Full IntroductionHide Full Introduction